BCL2 and rectal cancer: The aim of this study was to predict complete pathological tumour regression to preoperative HDREB by investigating the combined immunohistochemical expression of EGFR, VEGF, p53, Bcl-2 and APAF-1 in 104 pretreatment biopsies from patients with advanced rectal cancer.